IMMUTEP Ltd
Immutep develops immunotherapies for cancer and autoimmune disease, focusing on LAG-3-targeted therapeutics that stimulate or suppress immune responses.
6-KSep 22Latest SEC filing, period to Sep 21
Jul 13Latest story
July 2026
Sign inSign inImmutep develops immunotherapies for cancer and autoimmune disease, focusing on LAG-3-targeted therapeutics that stimulate or suppress immune responses.